A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Trial Profile

A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC)

Completed
Phase of Trial: Phase I/II

Latest Information Update: 20 Apr 2016

At a glance

  • Drugs Carotuximab (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 20 Apr 2016 Results (n = 20) presented at the 107th Annual Meeting of the American Association for Cancer Research.
    • 11 Apr 2016 Data will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2016, according to a TRACON Pharmaceuticals media release.
    • 12 Feb 2015 Treatment arms changed from 2 to 6, dose 20mg is included now. Also focused is only AR now as (progression free survival) primary end point is deleted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top